A WORLD OF CARE
Biologic medicines have become the standard of care for many serious diseases.
biosimilars without borders
Mylan's belief is that 7 billion people across the globe deserve access to the treatments they need. As one part of this broader cause, we are working to make biologics more accessible.
WHAT ARE BIOSIMILARS
marvels of modern science
Biologics have revolutionized the treatment of many diseases. Biosimilar medicines offer physicians additional therapeutic options to important, but often expensive, reference products.
Biologics are highly complex and often expensive therapies.
A biosimilar is a biologic deemed highly similar to an already approved biologic medicine, known as a reference product. This similarity is confirmed through a number of tests, both in the lab and in clinical research.
A biosimilar manufacturer must demonstrate that its proposed biosimilar product has no clinically meaningful differences from the reference product in terms of safety, purity, and effectiveness.
-
WHAT IS A BIOSIMILAR?
Biologics are highly complex and often expensive therapies.
A biosimilar is a biologic deemed highly similar to an already approved biologic medicine, known as a reference product. This similarity is confirmed through a number of tests, both in the lab and in clinical research.1
A biosimilar manufacturer must demonstrate that its proposed biosimilar product has no clinically meaningful differences from the reference product in terms of safety, purity, and effectiveness.
-
WHAT IS A BIOSIMILAR?
Biologics are highly complex and often expensive therapies.
A biosimilar is a biologic deemed highly similar to an already approved biologic medicine, known as a reference product. This similarity is confirmed through a number of tests, both in the lab and in clinical research.
A biosimilar manufacturer must demonstrate that its proposed biosimilar product has no clinically meaningful differences from the reference product in terms of safety, purity, and effectiveness.
EXPANDING ACCESS
we reach people
The most advanced drugs are of no use if patients don’t have access to them. Biologics are a case in point.
Only 2% of the U.S. population uses biologics, but they account for 40% of prescription drug spending. Of the top 20 most costly drugs in the world, 12 of them are biologics, representing ~$100 billion of the ~$153 billion spent on these medicines; Mylan has 9 of these products on the market or in its global product pipeline.
There is an urgent need for increased access to biologics in many underserved regions, countries and emerging markets around the world.
Mylan has successfully introduced biosimilars in 35 countries. What others hope to do in the future, Mylan is delivering today.
For nearly 60 years, Mylan’s mission has been to provide access to medicine. Today our workforce of ~35,000 serves patients in >165 countries and territories, and we offer a growing portfolio of more than 7,500 medicines, including branded, generic and consumer health products. You may not realize that Mylan provides ~69 billion doses of medicine annually.
Biosimilars play an important role in our commitment by offering additional therapeutic options to more expensive biologics, and potentially increasing access to treatment. It's not just patients who may benefit - governments and insurers may, too.
-
NO MATTER WHERE
35 COUNTRIES GLOBALLY
There is an urgent need for biologics in many underserved regions, countries and emerging markets around the world.
Mylan has successfully introduced biosimilars in 35 countries. What others hope to do in the future, Mylan is delivering today.
-
ITS WHAT WE DO
For nearly 60 years, Mylan’s mission has been to provide access to medicine. Today our workforce of ~35,000 serves patients in >165 countries and territories, and we offer a growing portfolio of more than 7,500 medicines, including branded, generic and over-the-counter products. You may not realize that Mylan provides ~69 billion doses of medicine annually.
Biosimilars play an important role in our commitment by offering additional therapeutic options to more expensive biologics, and potentially increasing access to treatment. It's not just patients who benefit - governments and insurers do, too.
A COMMITMENT TO BIOSIMILARS
biosimilars value
Every biosimilar we add to our portfolio may help provide more patients in more countries with the treatment they need. We are committed to continuing to invest in biosimillars.
We have one of the industry’s largest and most diverse global portfolios: including 20 biosimilars and insulin analogs.
Our portfolio includes many of the top biologics globally and focuses on the areas of oncology, immunology, endocrinology and ophthalmology.
Biosimilars play an important role in our commitment by offering additional therapeutic options to more expensive biologics.
It is projected that biosimilars will potentially generate a savings of $54 billion in direct spending on biologic drugs in the U.S. between 2017 and 2026.2
-
A GROWING PORTFOLIO
We have one of the industry’s largest and most diverse portfolios: including 20 biosimilars and insulin analogs.
Our portfolio includes many of the top biologics globally and focuses on the areas of oncology, immunology, endocrinology and ophthalmology.
-
INDUSTRY-WIDE SAVINGS
$52 B POTENTIALLY
SAVED OVER 9 YEARSBiosimilars play an important role in our commitment by offering additional therapeutic options to more expensive biologics.
It is projected that biosimilars will generate a savings of $54 billion in direct spending on biologic drugs in the U.S. between 2017 and 2026.
MANUFACTURING EXPERTISE
experience that counts
Both reference products and biosimilar medicines are made under carefully controlled conditions, known as Good Manufacturing Practices (GMP), to ensure that they are consistently produced to the required quality.
Mylan has made medicines for nearly 60 years and has a long history of manufacturing complex products.
Of our nearly 50 manufacturing sites around the world, 10 focus on product technology development, including biosimilars and respiratory products. One of our complex analytical laboratories is located in Morgantown, West Virginia and is helping us lead the way in biosimilar development.
-
CENTERS OF EXCELLENCE
CONTACT US
we’re easy to access
Corporate Office
Mylan, Inc.
1000 Mylan Boulevard
Canonsburg, PA 15317
Contact Mylan
-
CENTERS OF EXCELLENCE
Corporate Office Mylan, Inc.
1000 Mylan Boulevard
Canonsburg, PA 15317
Contact Mylan
MYLAN and the Mylan logo are registered trademarks of Mylan Inc.
© 2020 Mylan N.V. All rights reserved.
NON-2019-2151
References:
1. https://www.fda.gov/drugs/biosimilars/biosimilar-development-review-and-approval
2. Biosimilar Cost Savings in the United States: Initial Experience and Future Potential. (2017-2026). RAND Corporation, 2017.
